Polyphor Provides Update on the Phase III FORTRESS Study of Balixafortide in Patients with Advanced HER2 Negative Breast Cancer

Polyphor AG announced that its global Phase III study, FORTRESS, evaluating balixafortide in combination with eribulin for the treatment of patients with HER2 negative, locally recurrent or metastatic breast cancer, did not meet its co-primary endpoint.